Literature DB >> 6092896

Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors.

R R Trifiletti, S H Snyder.   

Abstract

The interactions of zopiclone and suriclone, representatives of nonbenzodiazepine cyclopyrrolone anxiolytics, with central-type benzodiazepine receptors have been characterized in rat and bovine brain. While zopiclone potently (IC50 approximately 50 nM) inhibits [3H]Ro-15-1788 binding in an apparent mass action fashion, suriclone and its metabolite 35,489 RP are extremely potent (IC50 approximately 350 pM and 1 nM, respectively) and display Hill coefficients of approximately 2.0. Like classical benzodiazepines, none of the cyclopyrrolones studied display selectivity for type I or type II benzodiazepine receptors. Using [3H]suriclone, saturable high affinity sites for cyclopyrrolone anxiolytics were directly labeled in rat and bovine brain. The regional distribution and pharmacologic specificity of [3H]suriclone and [3H]Ro-15-1788 binding sites are similar, suggesting that [3H]suriclone recognition sites reside on the benzodiazepine receptor complex. Unlike classical benzodiazepine agonists, such as diazepam, the binding of [3H]suriclone is not modulated by GABA, Cl-, pentobartibal, or tracazolate. Unlike those of [3H]diazepam, [3H]suriclone-binding sites are only minimally affected by photoaffinity labeling with flunitrazepam. Whereas the binding affinities of [3H]Ro-15-1788, [3H]flunitrazepam, and [3H]ethyl beta-carboline 3-carboxylate increase at lower temperatures, [3H]suriclone binds with higher affinity at higher temperatures. Scatchard analysis of [3H]flunitrazepam, [3H]ethyl beta-carboline 3-carboxylate, and [3H]Ro-15-1788 binding in the presence of all cyclopyrrolones studied reveals an apparent noncompetitive pattern of inhibition of binding in each case; by contrast, inhibition of [3H]suriclone binding by Ro-15-1788 flunitrazepam, methyl beta-carboline 3-carboxylate and all of the cyclopyrrolones studied appears competitive. The dissociation kinetics of [3H]Ro-15-1788 indicate that cyclopyrrolones, but not benzodiazepines, increase the dissociation rate of [3H]Ro-15-1788 from its membrane receptors; the converse is true for [3H]suriclone dissociation kinetics. The association kinetics of [3H]suriclone suggest that suriclone induces a conformational change upon binding to receptors. Taken together, these results indicate that [3H]suriclone labels a site on the benzodiazepine receptor complex allosteric to the recognition site for benzodiazepines. A model is proposed to describe the interaction between benzodiazepines and cyclopyrrolones.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092896

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  19 in total

1.  Intraocular pressure in anaesthetized dogs given flumazenil with and without prior administration of midazolam.

Authors:  A A Artru
Journal:  Can J Anaesth       Date:  1991-04       Impact factor: 5.063

2.  Effects of non-sedative anxiolytic drugs on responses to GABA and on diazepam-induced enhancement of these responses on mouse neurones in cell culture.

Authors:  P P De Deyn; R L Macdonald
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

3.  Heterogeneous distribution of benzodiazepine receptors among rat neostriatal neurones.

Authors:  M Munakata; R Nakanishi; N Akaike
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

4.  Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects.

Authors:  H V Semlitsch; P Anderer; B Saletu
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder.

Authors:  M Ansseau; J P Olié; R von Frenckell; G Jourdain; B Stehle; P Guillet
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests.

Authors:  T Kuitunen; M J Mattila; T Seppälä; K Aranko; M E Mattila
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

7.  Pharmacokinetic and -dynamic studies with a new anxiolytic, suriclone, utilizing EEG mapping and psychometry.

Authors:  B Saletu; J Grünberger; L Linzmayer; H V Semlitsch; P Anderer; K Chwatal
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

Review 8.  The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes.

Authors:  W Hevers; H Lüddens
Journal:  Mol Neurobiol       Date:  1998-08       Impact factor: 5.590

Review 9.  Rebound insomnia and newer hypnotics.

Authors:  M Lader
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists.

Authors:  Y C Martin; M G Bures; E A Danaher; J DeLazzer; I Lico; P A Pavlik
Journal:  J Comput Aided Mol Des       Date:  1993-02       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.